19 suspended. 19 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Suspended 19 |
| Phase 2 | 11 | Suspended 11 |
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), Aspirin Tablet - Cerebral Infarction | Phase 1 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium - Cerebral Infarction | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-04 | 2026-10-30 |
| CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Suspended | Thomas Martin, MD | 30 | 2026-02-28 | 2026-06-11 |
| External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Extramedullary Disease in Multiple Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Suspended | City of Hope Medical Center | 20 | 2025-08-29 | 2026-10-07 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Iberdomide, Belantamab Mafodotin, Dexamethasone - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Alliance for Clinical Trials in Oncology | 88 | 2025-04-23 | 2026-10-02 |
| GRAViceptive NEGlect Treatment in Acute Stroke Using Targeted Cranial ELECTrotherapy Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS), Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS) - Stroke | Phase 1 / Phase 2 | Suspended | University of Sao Paulo | 28 | 2025-01-03 | 2026-07-10 |
| NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU) NOX-1416+SOC, Placebo+SOC - Diabetic Foot Ulcer | Phase 1 | Suspended | NOxy Health Products, LLC | 30 | 2023-08-16 | 2024-01-16 |
| SY007 in Patients With Acute Ischemic Stroke SY-007/ Placebo 15mg, SY-007/ Placebo 30mg, SY-007/ Placebo 60mg - Acute Ischemic Stroke | Phase 1 | Suspended | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | 36 | 2023-07-01 | 2022-06-27 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib, Iberdomide, Oral Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Hackensack Meridian Health | 66 | 2022-05-13 | 2026-07-13 |
| Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma NEXI-002 T Cells - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | NexImmune Inc. | 9 | 2020-08-17 | 2024-01-16 |
| CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma CS1-CAR T Therapy, Cyclophosphamide, Fludarabine - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Suspended | City of Hope Medical Center | 30 | 2019-04-23 | 2026-10-30 |
| Pilot Trial: the Safety and Feasibility of Losartan for Pulmonary Vein Stenosis Losartan - Pulmonary Vein Stenosis, Children | Phase 1 / Phase 2 | Suspended | The Hospital for Sick Children | 40 | 2016-05-01 | 2019-07-30 |
| Pulmonary Protection of Transcutaneous Electrical Acupoint Stimulation in Gynecologic Laparoscopic Surgery electroacupuncture - Reperfusion Injury | Phase 1 / Phase 2 | Suspended | Shengjing Hospital | 100 | 2015-03-01 | 2016-08-01 |
| Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients Mesenchymal cell therapy - Coronary Disease, Heart Transplant | Phase 1 / Phase 2 | Suspended | Assistance Publique - Hôpitaux de Paris | 14 | 2014-01-01 | 2017-02-23 |
| Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec) - Refractory Angina Pectoris | Phase 1 | Suspended | Medispec | 20 | 2009-03-01 | 2012-04-03 |
| Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction Post conditioning, Usual Care for STEMI - Acute Myocardial Infarction | Phase 1 | Suspended | University of Cincinnati | 30 | 2008-03-01 | 2014-02-03 |
| Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2 M40403 - IL-2 Induced Hypotension | Phase 1 / Phase 2 | Suspended | MetaPhore Pharmaceuticals | 48 | 2001-12-01 | 2005-06-24 |
Multiple Myeloma (8) · Cerebral Infarction (2) · Angina Pectoris (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Coronary Disease (1) · Diabetic Foot (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Hypotension (1) · Ischemic Stroke (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
Cardiovascular Diseases (19) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Blood Protein Disorders (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms, Plasma Cell (8) · Paraproteinemias (8) · Pathological Conditions, Signs and Symptoms (6)
Cyclophosphamide (3) · Magnetic Resonance Spectroscopy (3) · Biopsy (2) · Dexamethasone (2) · Leukapheresis (2) · Specimen Handling (2) · fludarabine (2) · iberdomide (2) · Aspirin (1) · Atorvastatin (1) · Congresses as Topic (1) · Electroacupuncture (1) · IL32 protein, human (1) · Image-Guided Biopsy (1) · Immunotherapy, Adoptive (1)
City of Hope Medical Center (2) · Sclnow Biotechnology Co., Ltd. (2) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · David Wald (1) · Hackensack Meridian Health (1) · Medispec (1) · MetaPhore Pharmaceuticals (1) · NOxy Health Products, LLC (1) · National Cancer Institute (NCI) (1) · NexImmune Inc. (1) · Shengjing Hospital (1) · Suzhou Yabao Pharmaceutical R&D Co., Ltd. (1) · The Hospital for Sick Children (1) · Thomas Martin, MD (1)
United States (10) · China (4) · Canada (2) · Brazil (1) · France (1) · Israel (1)
Anupama Kumar, MD (1) · Arvi Grover, MD (1) · Benjamin Tomlinson, MD (1) · Christopher A Caldarone, MD (1) · Elizabeth M Hill, M.D. (1) · Gabriel Halperin, MD (1) · Junchao Zhu, doctor (1) · Kristi Jones (1) · Lei Guo, Dr (1) · Lei Guo, Dr. (1) · Myo Htut (1) · Noa Biran, MD (1) · Richard Isnard, MD, PhD (1) · Scott R Goldsmith (1) · Taiza Edwards, PhD (1)
2023 (1), P30CA033572 (1)